Palisade Bio, Inc. (PALI)
Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing oral therapies that target serious diseases associated with the breakdown of the mucosal barrier protecting the gastrointestinal tract. Its lead therapeutic candidate is LB1148, an oral liquid formulation of the digestive enzyme inhibitor that is intended to inhibit digestive enzyme activity and preserve gut integrity during intestinal stress resulting from reduced blood flow to the intestine, infections, or due to surgery. The company was founded in 2005 and is headquartered in Carlsbad, California.
$4.76M
Mr. J. D. Finley
13.00
Carlsbad, CA
Dec 20, 2006
-0.22
$-18.57
4.00
4.31
5,669.60%
-0.35
-0.00
0.50
-19.32
4.31
-110.12%
-124.86%
Similar stocks (8)
Immix Biopharma, Inc.
IMMX
Unicycive Therapeutics, Inc.
UNCY
Virios Therapeutics, Inc.
VIRI
Enveric Biosciences, Inc.
ENVB
Phio Pharmaceuticals Corp.
PHIO
NovaBay Pharmaceuticals, Inc.
NBY
eFFECTOR Therapeutics, Inc.
EFTR
Navidea Biopharmaceuticals, Inc.
NAVB
ETF Exposure (2)
Vanguard Extended Market Index Fund Institutional Shares
VIEIX
0%
Vanguard Extended Market Index Fund
VXF
0%
Similar stocks (8)
Immix Biopharma, Inc.
IMMX
Unicycive Therapeutics, Inc.
UNCY
Virios Therapeutics, Inc.
VIRI
Enveric Biosciences, Inc.
ENVB
Phio Pharmaceuticals Corp.
PHIO
NovaBay Pharmaceuticals, Inc.
NBY
eFFECTOR Therapeutics, Inc.
EFTR
Navidea Biopharmaceuticals, Inc.
NAVB
ETF Exposure (2)
Vanguard Extended Market Index Fund Institutional Shares
VIEIX
0%
Vanguard Extended Market Index Fund
VXF
0%